Can plant-derived anti-HIV compounds be used in COVID-19 cases?. (September 2022)

• Record Type: Journal Article
• Authors: Das, Diptimayee; Bihari Jena, Atala; Banerjee, Antara; Kumar Radhakrishnan, Arun; Duttaroy, Asim K.; Pathak, Surajit
• Is Part Of: Medical hypotheses. Volume 166(2022)
• Publication Date: 2022-09
• Subjects: HIV -- Covid-19 -- ACE2 -- S protein -- Calanolides A -- Holy Basil -- Kuwanon-L -- Patentiflorin A; ACE2 Angiotensin-converting enzyme-2 -- HIV Human Immunodeficiency Virus -- AIDS Acquired immunodeficiency syndrome -- NETs neutrophil extracellular traps -- CD4 Cluster of Differentiation 4 -- SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 -- AZT Azidothymidine -- NRTIs nucleoside analog reverse transcriptase inhibitor -- NNTRIs Non-nucleoside analogs transcriptase reverse inhibitor -- RT Reverse Transcriptase -- IN Integrase -- HAART Highly active antiretroviral therapy, ART, Antiretroviral therapy; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Medicine; Periodicals; 610
• DOI: 10.1016/j.mehy.2022.110926
• Languages: English
• ISSNs: 0306-9877

Abstract

Abstract: People living with HIV are more exposed to the adverse health effects of the worldwide COVID-19 pandemic. The pandemic's health and social repercussions may promote drug abuse and inadequate HIV management among this demographic. The coronavirus pandemic of 2019 (COVID-19) has caused unprecedented disruption worldwide in people's lives and health care. When the COVID-19 epidemic was identified, people with HIV faced significant obstacles and hurdles to achieving optimal care results. The viral spike protein (S-Protein) and the cognate host cell receptor angiotensin-converting enzyme 2 (ACE2) are both realistic and appropriate intervention targets. Calanolides A, Holy Basil, Kuwanon-L, and Patentiflorin have anti-HIV effects. Our computational biology study investigated that these compounds all had interaction binding scores related to S protein of coronavirus of −9.0 kcal /mol, −7.1 kcal /mol, −9.1 kcal /mol, and −10.3 kcal/mol/mol, respectively. A combination of plant-derived anti-HIV compounds like protease inhibitors and nucleoside analogs, which are commonly used to treat HIV infection, might be explored in clinical trials for the treatment of COVID-19.